{"entity": "researcher", "timestamp": "2026-09-23T21:55:01.322Z", "family": "Furu", "given": "Kari", "initials": "K", "orcid": "0000-0003-2245-0179", "affiliations": ["Department of Chronic Diseases and Ageing, Norwegian Institute of Public Health, Oslo, Norway.", "Center for Fertility and Health, Norwegian Institute of Public Health, Oslo, Norway."], "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/researcher/f00c9192b2a642869c13e93ca5526147.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/researcher/f00c9192b2a642869c13e93ca5526147"}}, "publications": [{"entity": "publication", "iuid": "491a452b3b0646278c44c993d28d3c25", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/491a452b3b0646278c44c993d28d3c25.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/491a452b3b0646278c44c993d28d3c25"}}, "title": "EpiCore-A Common Data Model for Pharmacoepidemiological Studies in Denmark, Norway, and Sweden.", "authors": [{"family": "Jensen", "given": "Peter Bj\u00f8dstrup", "initials": "PB", "orcid": "0000-0001-5435-9092", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/49e53e58a93c4cb49b089964ab105bd9.json"}}, {"family": "Andersen", "given": "Jacob H", "initials": "JH"}, {"family": "Ernst", "given": "Martin Thomsen", "initials": "MT"}, {"family": "Olesen", "given": "Morten", "initials": "M"}, {"family": "Karlstad", "given": "\u00d8ystein", "initials": "\u00d8", "orcid": "0000-0003-1204-787X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/444d55a5814c4342a44da5f6488b6e23.json"}}, {"family": "Furu", "given": "Kari", "initials": "K", "orcid": "0000-0003-2245-0179", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f00c9192b2a642869c13e93ca5526147.json"}}, {"family": "Eriksson", "given": "Julia", "initials": "J"}, {"family": "Gembert", "given": "Karin", "initials": "K"}, {"family": "Potteg\u00e5rd", "given": "Anton", "initials": "A", "orcid": "0000-0001-9314-5679", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/1daf4d9300f94bf6916f968437b52a80.json"}}], "type": "journal article", "published": "2025-11-00", "journal": {"title": "Pharmacoepidemiol Drug Saf", "issn": "1099-1557", "volume": "34", "issue": "11", "pages": "e70241", "issn-l": null}, "abstract": "The use of common data models (CDMs) is increasing; however, the complexity of many CDM frameworks constitutes a barrier for their use. For many local and collaborative use cases, simpler CDMs can suffice. Here, we propose the EpiCore CDM, a simple CDM framework for use in Scandinavian pharmacoepidemiological studies.\n\nThe EpiCore CDM was developed based on a set of guiding principles. It should (i) accommodate the most common elements of typical data sources in the field and region, (ii) be accessible to users without needing advanced technical expertise or database infrastructure, (iii) prioritize structural and syntactic harmonization of data and defer clinical concept mapping to the analytical phase, (iv) be usable in both collaborative and single site settings, and (v) include support for quality control procedures.\n\nThe EpiCore CDM comprises two mandatory administrative tables (person and observation), six optional event tables (diagnosis, procedure, encounter, drug, primcare, and cancer) and three optional lookup tables (drug_info, organisation_info, and prescriber_info). Each table, along with its columns and constraints is specified according to an EpiCore CDM specification template. This provides easy documentation and integrates with an R-package called EpiCoreAssistant, which provides quality control tools for testing the compliance of a CDM instance with the EpiCore specification. In the event that a project requires customization of the CDM, this is easily implemented in the template and testing. A step-by-step description is presented, demonstrating the steps involved in a typical CDM-based collaborative pharmacoepidemiological study using the EpiCore CDM.\n\nWe present the EpiCore CDM, a specification template and an R package that offers a simple framework for improved workflows, standardizations and collaboration, focused on Scandinavian pharmacoepidemiological studies and with relevance for a broad palette of register-based health care researchers.", "doi": "10.1002/pds.70241", "pmid": "41185087", "labels": [], "xrefs": [], "notes": [], "created": "2026-09-23T15:52:48.517Z", "modified": "2026-09-23T15:52:48.619Z"}, {"entity": "publication", "iuid": "d413d5d0e7b84b61a960fa93b787591a", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/d413d5d0e7b84b61a960fa93b787591a.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/d413d5d0e7b84b61a960fa93b787591a"}}, "title": "Use of sildenafil and other phosphodiesterase type 5 inhibitors among pregnant women in Scandinavia.", "authors": [{"family": "Cesta", "given": "Carolyn E", "initials": "CE", "orcid": "0000-0001-5759-9366", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/35e1b896082549c2b69ead371bf4e3a8.json"}}, {"family": "Segovia Chac\u00f3n", "given": "Silvia", "initials": "S", "orcid": "0000-0003-0210-5829", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/2e63ae649a0e4a18847b5e19d73ea48b.json"}}, {"family": "Engeland", "given": "Anders", "initials": "A", "orcid": "0000-0001-5620-9207", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/fa92583833b8407392fef0584366c87e.json"}}, {"family": "Broe", "given": "Anne", "initials": "A", "orcid": "0000-0002-4149-8808", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9ff2659b76694a548fb6a84225f90885.json"}}, {"family": "Damkier", "given": "Per", "initials": "P", "orcid": "0000-0003-0591-7187", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/3220b6c562f2497f9122594f270ba2ab.json"}}, {"family": "Furu", "given": "Kari", "initials": "K", "orcid": "0000-0003-2245-0179", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f00c9192b2a642869c13e93ca5526147.json"}}, {"family": "Kieler", "given": "Helle", "initials": "H", "orcid": "0000-0001-9338-7133", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/831da95a6b2f4a9b9e29aed574219101.json"}}, {"family": "Karlsson", "given": "P\u00e4r", "initials": "P", "orcid": "0000-0002-7177-1713", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9177884596f74f758d9a3cbfc472a8e0.json"}}], "type": "journal article", "published": "2021-11-00", "journal": {"title": "Acta Obstet Gynecol Scand", "issn": "1600-0412", "volume": "100", "issue": "11", "pages": "2111-2118", "issn-l": null}, "abstract": "For phosphodiesterase type 5 (PDE5) inhibitors, such as sildenafil, the only approved indication in women is for pulmonary arterial hypertension. These drugs are increasingly being proposed and tested for treatment of female infertility and complications in pregnancy. However, the extent of use of PDE5 inhibitors in the general pregnant population over the last decades is unknown. Therefore, we conducted a descriptive cohort study using data from the population health registers in the Scandinavian countries.\n\nBy linking the Medical Birth Registers and the Prescribed Drug Registers in Denmark (1997-2017), Norway (2004-2017), and Sweden (2006-2016), women with filled prescriptions of PDE5 inhibitors in outpatient settings in the 90 days before the date of last menstrual period and/or during pregnancies were identified. With additional linkage to the National Patient Registers, information on maternal, pregnancy, and infant characteristics, co-morbidities, and co-medication was collected and described.\n\nAmong over 3 million singleton pregnancies, only 77 were pregnancies in women who had at least one filled prescription of a PDE5 inhibitor within the 90 days before the start of pregnancy to delivery. Prescription fills most often occurred before the last menstrual period and in the first trimester, with very few occurring later in pregnancy. Sildenafil was the most used PDE5 inhibitor. Among pregnant women using PDE5 inhibitors, 44% were 35 years of age or older, eight had a cardiovascular diagnosis, and three specifically had a diagnosis of pulmonary arterial hypertension. Among the infants born to mothers using PDE5 inhibitors, nine were born preterm, six were small-for-gestational age, five had an Apgar score at 5 minutes below 8, 18 were admitted to the Neonatal Intensive Care Unit, and eight had respiratory and cardiovascular conditions.\n\nFew women used PDE5 inhibitors in outpatient settings before or during pregnancy in the Scandinavian countries in the last decades. Only a small proportion had a diagnosis for pulmonary arterial hypertension, suggesting off-label use in the remaining users. Use was predominantly in mothers over age 35 years. The safety of fetal exposure to sildenafil and other PDE5 inhibitors in pregnancy has not been established. As maternal age continues to increase and additional uses of PDE5 inhibitors are investigated, the safety of these drugs in pregnancy should be thoroughly evaluated.", "doi": "10.1111/aogs.14251", "pmid": "34453753", "labels": [], "xrefs": [], "notes": [], "created": "2026-09-23T13:11:17.932Z", "modified": "2026-09-23T13:11:18.147Z"}]}